C4 Therapeutics, Inc. — 2021 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2021, C4 Therapeutics was a clinical-stage biopharmaceutical company developing targeted protein degraders through its TORPEDO platform. It had no approved products and generated no product-sales revenue; reported revenue came from research collaboration and license agreements. Its lead candidate, CFT7455, entered a Phase 1/2 trial in June 2021. CFT8634’s IND was cleared in December 2021; CFT1946 and CFT8919 remained preclinical.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Collaboration revenue | $45.8 million | $33.2 million |
| Research and development expense | $94.7 million | $78.4 million |
| General and administrative expense | $33.3 million | $15.2 million |
| Total operating expenses | $127.9 million | $93.6 million |
| Loss from operations | $82.1 million | $60.4 million |
| Net loss | $83.9 million | $66.3 million |
| Net loss per share, basic and diluted | $1.82 | $5.83 |
| Net cash used in operating activities | $87.0 million | $67.2 million |
- Revenue increased 38%, while operating expenses increased 37%. Operating losses widened as R&D and G&A spending grew; the business remained unprofitable. Gross margin is not presented as a meaningful measure for this development-stage business.
- Cash, cash equivalents and marketable securities totaled $451.5 million at year-end, including $76.1 million of cash and equivalents and $375.4 million of marketable securities. Restricted cash was an additional $3.3 million.
- Financing cash flow included $169.5 million net proceeds from a June 2021 follow-on offering. The company reported no sales under its $200 million at-the-market program through year-end.
- Long-term debt had $12.5 million principal outstanding and a $10.8 million carrying value. The related-party loan bore 11.25% interest at year-end, required interest-only payments through December 2022, and matured June 2024.
- Current assets were $325.7 million and current liabilities $51.2 million. Deferred revenue totaled $56.2 million, reflecting amounts received but not yet recognized under collaborations.
Material changes versus the prior comparable period
- Collaboration revenue rose $12.6 million, including $12.6 million recognized when Roche and C4 mutually terminated the BRAF target arrangement. Biogen revenue also increased; Calico revenue declined.
- R&D expense rose $16.2 million, reflecting preclinical and IND-enabling work, hiring, and $2.7 million of clinical costs following CFT7455 trial initiation.
- G&A expense increased $18.1 million, driven in part by higher personnel and stock-based compensation and public-company expenses. Stock-based compensation totaled $21.5 million in 2021 versus $3.4 million in 2020.
- Cash used in operations increased $19.7 million. The 2021 net loss per share was lower than in 2020, in part because the weighted-average share count increased substantially after the 2020 IPO and preferred-stock conversion.
Outlook, risks and unusual items
- Management said available funds, together with expected collaboration payments, were expected to support its existing operating plan through the end of 2024. The financial-statement note separately states the $451.5 million balance was sufficient for at least 12 months from issuance; management cautions that estimates depend on assumptions. The company expects continuing losses and will need substantial additional capital to fund development through approval.
- Planned milestones included dosing the first CFT8634 patient in the first half of 2022, submitting an IND and beginning a CFT1946 trial in the second half of 2022, and completing CFT8919 IND-enabling activities by year-end 2022. These are forward-looking plans, not achieved outcomes.
- In August 2021, CFT7455 received FDA orphan drug designation for multiple myeloma. The company stated that expedited development or accelerated approval could be explored, but neither is assured.
- Key risks include clinical failure or safety issues, the unproven targeted-degradation approach, trial enrollment and COVID-19 disruption, reliance on third-party manufacturers and CROs, competition, intellectual-property challenges, collaboration-partner decisions, and the need for additional financing. The company had experienced some clinical-site delays and disclosed a prior manufacturing mechanical issue for CFT7455 that did not delay its IND submission.
- Roche returned CFT1946/BRAF rights to C4 for the degradation field in November 2021; Roche retained rights to pursue the target in its inhibition field. C4 also reported a lease amendment and additional Watertown space, with rent on the new space commencing in 2022.
- KPMG issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective controls and stated a prior journal-entry segregation-of-duties material weakness had been remediated.
Important facts for investors to verify
- Cash burn, collaboration receipts and whether the stated runway through 2024 remains supported by updated operating plans and financing assumptions.
- Clinical progress, enrollment, safety, dose selection and efficacy data for CFT7455 and subsequent trial starts for CFT8634 and CFT1946.
- Whether collaboration milestones or option exercises generate cash, and the timing and terms of any additional financing or ATM sales.
- Debt repayment and covenant requirements, including the 2024 maturity, and the financial effect of expanded lease commitments.
- Potential dilution from equity compensation, future share issuance and the company’s ability to protect relevant intellectual property.